Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HT547
- Development stage
- Phase 1
- Lead developer
- Huabang Pharmaceutical
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
HT547 is a radiopharmaceutical ligand designed to target the urokinase plasminogen activator receptor (uPAR), a cell-surface protein that is overexpressed in various solid tumors and plays a critical role in cancer cell migration, invasion, and metastasis. It is developed as a theranostic pair, consisting of a diagnostic imaging agent and a therapeutic agent. When labeled with the positron-emitting isotope Gallium-68 ([68Ga]Ga-HT547), it is used for PET/CT imaging to detect and localize uPAR-positive lesions. When labeled with the beta-emitting isotope Lutetium-177 ([177Lu]Lu-HT547), it serves as a targeted radionuclide therapy to deliver localized radiation to tumor cells. HT547 is currently being evaluated in early-phase clinical trials to assess its safety, biodistribution, and dosimetry in patients with solid tumors, including breast cancer, head and neck cancer, pancreatic cancer, and glioma.
- Other names
- 68Ga-HT547177Lu-HT547
02
Targets
PLAUR (Urokinase plasminogen activator receptor)
Beyond the preview
Go deeper on HT547.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HT547.